Immucell Overview
Immucell (ICCC) has a P/E ratio of 118.79, above the Healthcare sector average of 25.93.
Get informed when a big investor buys or sells
+ Follow118.79
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, ICCC shows a P/E ratio of 118.79. That is above the Healthcare sector average of 25.93. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 25.93. Immucell is at 118.79, which is higher that average. That is roughly 358.1% above the sector mean. Use the comparison chart on this page to see how ICCC stacks up against individual peers as well.
Investors watch ICCC's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Immucell's latest reading is 118.79. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Immucell's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 118.79) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 25.93, while ICCC is at 118.79. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
